Skip to main content

Table 2 Clinical characteristics of the 26 individuals genotyped in two families

From: Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum

Family/mutation

ID

Gender

Age (years)

OB/Age of onset (years)

BMI (Kg/m2)

BMI before T2D

T2D/Age of diagnosis (years)

FG (mg/dL)

HbA1c (%)

Previous diagnosis of Dyslipidemia/Age of diagnosis (years)

TG (mg/dL)

Chol (mg/dL)

HDL (mg/dL)

HTN/Age of diagnosis  (years)

SBP (mmHg)

DBP (mmHg)

F1/p.Arg252His

Non-carriers

IV.6

M

12

No

24

NA

No

89

No

145

174

35

No

115

71

IV.4

M

13

No

19.7

NA

No

83

5.3

No

86

110

41

No

114

58

IV.2

F

18

No

26.4

NA

No

83

5.3

No

109

209

73

No

104

68

III.7

M

42

Yes/42

31.6

NA

No

68

No

118

192

34

No

127

83

III.6

F

41

Yes/41

32.5

NA

No

67

5.5

No

83

143

31

No

110

71

Carriers

IV.5

M

11

Yes/Childhood

30

NA

No

98

5.5

No

130

138

49

No

108

65

III.10

F

34

Yes/Childhood

35.6

35.6

Yes/34

168

9.1

Yes/29

479

179

23

No

123

87

III.8

F

45

Yes/Childhood

36.7

42.3

Yes/43

165

7.7

Yes/44

412

192

36

No

106

66

III.5

M

46

Yes/Childhood

41.5

47.8

Yes/41

120

6.8

Yes/30

341

146

39

Yes/41

107

70

II.5

F

69

Yes/Childhood

33.8

35.7

Yes/41

124

8.9

Yes/62

249

241

57

Yes/62

145

72

Average ± SD carriers with T2D

48.5 ± 14.7

36.9 ± 3.2

40.3 ± 5.8*

39.7 ± 3.9

144.2 ± 25.7*

8.1 ± 1.0*

41.2 ± 15.4

370.2 ± 98.5

189.5 ± 39.4

38.7 ± 14.0

51.5 ± 14.8

120.2 ± 18.2

73.7 ± 9.1

F2/p.Lys68Gln

Non-carriers

III.21

M

11

No

18.6

NA

No

86

No

48

190

48

No

106

85

III.5

F

12

No

16.9

NA

No

75

No

75

132

38

No

106

65

III.20

F

14

No

25.4

NA

No

88

No

83

223

69

No

109

75

III.12

M

17

Yes/17

37

NA

No

90

No

106

211

32

No

126

79

III.2

F

22

No

21.5

NA

No

82

No

59

171

40

No

99

60

III.1

F

27

No

29.5

NA

No

75

No

87

168

41

No

102

43

III.10

M

35

No

20.7

NA

No

81

No

56

135

41

No

112

70

II.15

F

36

No

25.9

NA

No

94

No

79

107

40

No

117

79

II.13

F

41

No

24.5

NA

No

77

No

66

214

76

No

110

62

II.2

F

49

Yes/44

38.8

NA

No

109

6.1

No

105

131

29

Yes/44

132

87

II.1

F

50

Yes/50

31.4

NA

No

89

No

85

174

48

No

134

76

I.2

F

70

No

20.7

NA

No

85

No

75

203

71

No

122

72

Carriers

III.19

M

18

No

26.4

NA

No

102

5.9

Yes/16

125

123

28

No

131

74

III.18

M

27

Yes/Childhood

40.4

50.8

Yes/18

276

12.5

Yes/24

231

192

38

No

137

83

II.14

M

40

Yes/Childhood

51.9

55.6

Yes/29

257

14.5

Yes/37

650

245

NA

Yes/40

149

87

II.12

F

49

Yes/Childhood

33.4

50.8

Yes/31

228

11.2

Yes/31

226

166

42

Yes/45

128

64

 

Average ± SD carriers with T2D

38.7 ± 11

41.9 ± 9.3

52.4 ± 2.8*

26 ± 7

253.6 ± 24.1*

12.7 ± 1.7*

30.67 ± 6.51

369 ± 243.3

201 ± 40.2

40 ± 2.8

42.5 ± 3.5

138 ± 10.5

78 ± 12.2

  1. ID, identification; OB, obesity; BMI, body mass index; T2D, type 2 diabetes; FG, fasting glucose; HbA1c, glycosylated hemoglobin; TG, triglyceride; Chol, total cholesterol; HDL, high density lipoprotein; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; M, male; F, female; NA, not apply; †, referred value by the patient; SD, standard deviation.
  2. *Adjusted p-value by gender < 0.05 when contrast average value of p.Arg252His with T2D and the average value of p.Lys68Gln with T2D